Treatment of cutaneous leishmaniasis with long-pulsed Nd:YAG laser in comparison with intralesional sodium stibogluconate or ciprofloxacin
DOI:
https://doi.org/10.66344/jpad.v34i4.2725Keywords:
Cutaneous Leishmaniasis, Nd:YAG Laser, Sodium Stibogluconate, Ciprofloxacin, Treatment ComparisonAbstract
Objective Cutaneous leishmaniasis (CL), a significant public health issue, is caused by a parasitic infection. This research aimed to assess the effectiveness and safety of long-pulsed Nd:YAG laser therapy in treating CL, and to compare its outcomes with treatments using intralesional sodium stibogluconate and 0.2% ciprofloxacin.
Methods In this study, 26 patients with a total of 73 cutaneous leishmaniasis lesions were divided into three groups for treatment. Group one, with 28 lesions, received long-pulsed Nd:YAG laser therapy. Group two, comprising 19 lesions, was treated with intralesional sodium stibogluconate, while group three, with 26 lesions, received intralesional 0.2% ciprofloxacin. Treatment efficacy was categorized into four levels: mild, moderate, marked, and complete clinical response. Treatments occurred bi-weekly over six weeks, followed by a three-month post-treatment follow-up to check for any complications.
Results Twenty-six patients with 73 cutaneous leishmaniasis lesions participated. Among them, 18 (69.2%) were male, and 8 (30.8%) were female. The treatment success rates were 82.1% for long-pulsed Nd:YAG laser, 78.9% for intralesional sodium stibogluconate, and 84.6% for intralesional ciprofloxacin. Throughout the treatment and follow-up period, no significant side effects or complications were observed in any of the three groups.
Conclusion Long-pulsed Nd:YAG laser seems to be comparable to both intralesional sodium stibogluconate and intralesional 0.2% ciprofloxacin in the treatment of cutaneous leishmaniasis.
References
1. Siadat AH, Zolfaghari A, Shahmoradi Z, Shariat S, Sohrabi K. Application of laser for treatment of cutaneous leishmaniasis: A review of literature. Lasers Med Sci. 2020;35(7):1451-7.
2. Sharquie KE, Noaimi AA, Al-Ghazzi AG. Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study). J Dermatol Dermatol Surg. 2015;19(2):108-13.
3. Bravo FG. Protozoa and Worms. In: Bolognia JL, Schaffer JV, Cerroni L (Eds). Dermatology. 4th ed. Elsevier; 2018.1470-1502.
4. Downing C, Tyring S. Parasitic diseases. In: Griffiiths CE, Barker J, Bleiker T (Eds). Rook's textbook of dermatology. 9th ed. West Sussex:Wiley Blackwell; 2016.1016-9.
5. Naif A, Hasan H, Kadhim K. Metronidazole versus Pentostam for treatment of cutaneous leishmaniasis. Gazz Med Ital. 2018;177(11):611-6.
6. Al-Heany AR, Sharquie KE, Al-Najar SA, et al. Cutaneous leishmaniasis: Comparative techniques for diagnosis. IOSR J Dent Med Sci. 2014;13:33-7.
7. Malek JM, Ghosn SH. Leishmaniasis and other protozoan infections. In: Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds). Fitzpatrick's dermatology in general medicine. 8th ed. New York: The McGraw-Hill Companies; 2012:2526-44.
8. Sharquie KE, Noaimi AA, Saleh BA. Cutaneous leishmaniasis as imitator of skin diseases and a diagnostic challenge. J Cosmet Dermatol Sci Appl. 2018;8:158-77.
9. Eiras DP, Kirkman LA, Murray HW. Cutaneous leishmaniasis: current treatment practices in the USA for returning travelers. Curr Treat Options Infect Dis. 2015;7(1):52–62.
10. Waller DG, Sampson AP (Eds). Medical pharmacology and therapeutics. 5th ed. Elsevier; 2018.
11. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: Clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg. 2017;96(1):24-45.
12. Al Hamdi K, Awad AH, Moker HM. Evaluation of intralesional 0.2% ciprofloxacin as a treatment for cutaneous leishmaniasis. East Mediterr Health J. 2010;16(1):89-93.
13. Sharquie KE. A new intralesional therapy of cutaneous leishmaniasis with hypertonic sodium chloride solution. J Dermatol. 1995;22(10):732-7.
14. Sharquie KE, Najim RA, Farjou IB. A comparative control trail of intralesional administrated zinc sulfate, hypertonic saline chloride and pentavalent antimony compound against acute cutaneous leishmaniasis. Clin Exp Dermatol. 1997;22(4):169-73.
15. Al-Waiz M, Sharquie KE, Al-Assir M. Treatment of cutaneous leishmaniasis by intralesional metronidazole. Saudi Med J. 2004;25:1512-3.
16. Sharquie KE, Noaimi AA, Sharara ZA, Saleh B, Al-Salam W. Topical therapy of acute cutaneous leishmaniasis using zinc sulphate solution 25% versus podophyllin solution 25%. J Cosmet Dermatol Sci Appl. 2017;7(03):258-74.
17. Kaufman J. Nd:YAG laser. In: Bard S, Goldberg DJ (Eds). Laser treatment of vascular lesions. Basel: Karger. 2014:94–106.
18. Steiner R. Basic laser physics. In: Raulin C, Karsai S (Eds). Laser and IPL technology in dermatology and aesthetic medicine. Springer-Verlag Berlin Heidelberg; 2011:2-22.
19. Sabaa HS, Zghair KH, Mohammed NR, Musa IS, Abd RS. The effect of Nd:YAG lasers on leishmania donovani promastigotes. World J Exp Biosci. 2016;4:25-8.
20. Omidian M, Jadbabaei M, Omidian E, Omidian Z. The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate. Postepy Dermatol Alergol. 2019;36(2):227–31.
21. Yanik M, Gurel MS, Simsek Z, Kati M. The psychological impact of cutaneous leishmaniasis. Clin Exp Dermatol. 2004;29(5):464-7.
22. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43(4):281-3.
23. Salmanpour R, Razmavar MR, Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2006;45(9):1115-6.
24. Al-Sabak H, Al-Dhalimi MA, Ali WA. Treatment of verruca vulgaris with long pulsed Nd:YAG laser 1064 nm in Iraqi patients. Kufa J Nurs Sci. 2019;9(1):1-10.
25. El-Sayed M, Anwar AE. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. J Eur Acad Dermatol Venereol. 2010;24(3):335-40.
26. Sharquie KE, Al-Talib KK, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol. 1988;119(1):53-7.
27. Ghos S. Evaluation of sodium stibogluconate in treatment of cutaneous leishmaniasis. Curr Med Res Opin. 1978;6:280-3.
28. Faris RM, Jarallah JS, Khoja TA, al-Yamani MJ. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol. 1993;32:610-12.
29. Arshad AR, Arshad A. Intralesional ciprofloxacin for cutaneous leishmaniasis: Comparison with meglumine antimoniate. Pak J Med Sci. 2011;27(3):566-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Khalil I. Al-Hamdi, Anwar Qais Saadoon
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
